Cell and gene therapies
One-time treatments with high upfront costs and uncertain long-term benefits relying on extrapolated ‘cure’ assumptions, often needing outcomes-based payment models.
Who we are
Independent thinking.
Independent thinking.
A shared ambition to make a difference.
A specialist team of health economists, market access strategists, and code builders collaborating to increase the net amount of good in the world.
Our experience
Expertise across complex therapeutic areas
We have experience partnering with clients to drive access for innovative treatments in the most important indications of the 21st century, and despite this deep knowledge we don’t rely on precedent to guide us.
We relish the challenge inherent in opening the doors to access for some of the most complex and intractable health conditions in the world.
The access challenge
Rare diseases
Small patient populations translate into small, single-arm trials, designed around surrogate outcomes over abbreviated time horizons. Payers expect risk-sharing through restrictions or discounts.
Neurodegenerative disorders
Slow-moving disease progression means uncertain clinical benefits derived from surrogate endpoints are often heavily discounted, with underrepresented impact on informal caregivers and the social care system.
Obesity and metabolic disease
Cost-effective on an individual basis but very large eligible populations mean access is often restricted to comorbid indications where the benefits of preventative effect are already diminished.
Immunology
Crowded drug classes, perceptions of therapeutic equivalence, and biosimilar price erosion mean payers demand head-to-head data or comprehensive NMAs, and implement strict line of therapy rules and switching algorithms.
Oncology
High population spend, combination therapy complications, and reliance on overall survival (OS) as the driver of value result in managed access or outcomes-based agreements, and access restricted to biomarker-defined populations.
Rooted in Canada and the UK. Global in outlook.
Our team brings decades of experience unlocking access and reimbursement across North America, Europe, MENA, and Australia.
Borders aren't barriers to our analyses; they shouldn't be barriers to health technologies.
Why Ammonite?
Ammonitida or 'true ammonites' evolved 200 million years ago and rapidly became ubiquitous in the world’s shallow oceans.
Their rapid evolutionary bursts followed by widespread dispersion allow geologists to use them as index fossils, marking the transition of one era to the next.
Ammonite fossils from the same eras are found around the UK coastline and across Western Canada.
These fossils vary in scale, intricacy, and value, but all with the same underlying morphology that underpinned their success for nearly 140 million years.
Rapid evolution marking a new era?
The name was a natural fit for our company.
It’s also fun to say out loud.
Ammonite Insights.
LET'S TALK
Start a conversation What is your next challenge?
Explore how Ammonite can support your evidence, modelling, or access decisions.